Exhibit 31.2                      CERTIFICATIONS

I, Robert Hipple, principal financial officer of TheraBiogen, Inc.
or "Registrant) certify that:


1. I have reviewed this quarterly report on Form 10-Q of the Company;

2. Based on my knowledge, this quarterly report does not contain any
Untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the
period covered by this quarterly report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
Registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined
in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over
financial
reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
Company and have:

                  (a) Designed such disclosure controls and procedures, or
         caused such disclosure controls and procedures to be designed under
         my supervision, to ensure that material information relating to the
         registrant, is made known to us by others within Company,
         particularly during the period in which this report is being
prepared;
                  (b) Designed such internal control over financial
reporting,
         or caused such internal control over financial reporting to be
          designed under our supervision, to provide reasonable assurance
	   regarding the reliability of financial reporting and the preparation
         of financial statements for external purposes in accordance with
         generally accepted accounting principles;
                  (c) Evaluated the effectiveness of the registrant's
         disclosure
         controls and procedures and presented in this report our conclusions
         about the effectiveness of the disclosure controls and procedures,
as
         of the end of the period covered by this report based on such
         evaluation; and
                  (d) Disclosed in this report any change in the registrant's
         internal control over financial reporting that occurred during the
         Company's fourth fiscal quarter that has materially affected, or is
         reasonably likely to materially affect, the Company's internal
         control over financial reporting; and

5. The Registrant's other certifying officers and I have disclosed, based on
our most recent evaluation, to the registrant's auditors and the audit
committee of  registrant's board of directors (or persons performing the
equivalent
function):

     a. all significant deficiencies in the design or operation of internal
     controls which could adversely affect the registrant's ability to
record,
     process, summarize and report financial data and have identified for the
     registrant's auditors any material weaknesses in internal controls; and
     b. any fraud, whether or not material, that involves management or other
     employees who have a significant role in the registrant's internal
     controls; and

6. The Registrant's other certifying officers and I have indicated in this
annual report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal
controls
subsequent to the date of our most recent evaluation, including any
corrective
actions with regard to significant deficiencies and material weaknesses.


Date: May 15, 2009                       /s/ Robert Hipple
                                         -----------------------------
                                         Robert Hipple,
                                         Principal financial officer